Sefik, Esen https://orcid.org/0000-0002-6807-3498
Israelow, Benjamin https://orcid.org/0000-0002-1308-8246
Mirza, Haris
Zhao, Jun
Qu, Rihao
Kaffe, Eleanna
Song, Eric https://orcid.org/0000-0001-5448-5865
Halene, Stephanie https://orcid.org/0000-0002-2737-9810
Meffre, Eric
Kluger, Yuval https://orcid.org/0000-0002-3035-071X
Nussenzweig, Michel https://orcid.org/0000-0003-0592-8564
Wilen, Craig B. https://orcid.org/0000-0003-2495-9403
Iwasaki, Akiko https://orcid.org/0000-0002-7824-9856
Flavell, Richard A. https://orcid.org/0000-0003-4461-0778
Funding for this research was provided by:
Howard Hughes Medical Institute
Damon Runyon Cancer Research Foundation (DRG-2316-18)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (2T32AI007517, AI061093, AI118855, K08AI128043, R01AI157488)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F30CA239444, U01CA260507, CA016359)
https://www.mercatus.org/emergent-ventures
G. Harold and Leila Y. Mathers Foundation
G. Harold and Leila Y. Mathers Foundation
Burroughs Wellcome Fund
Robert E. Leet and Clara Guthrie Patterson Trust
G. Harold and Leila Y. Mathers Foundation
https://www.mercatus.org/emergent-ventures http://www.ludwick.org/
G. Harold and Leila Y. Mathers Foundation
Bill and Melinda Gates Foundation
Article History
Received: 26 February 2021
Accepted: 5 November 2021
First Online: 17 December 2021
Competing interests
: R.A.F. is an advisor to GlaxoSmithKline, Zai Lab and Ventus Therapeutics.
Free to read: This content has been made available to all.